Analysis: A tale of three pharma companies and a quarter

Indian pharma companies cannot risk their prospects by under-performing when the external business environment and investor sentiment has improved for Indian pharma sector and those with flawed business models, ineffective strategies or non-agile operations are likely to face the brunt on the Street.
Three leading pharma companies announced June quarter results towards the end of the week – each with different levels of performances and investment prospects.
Cadila Healthcare reported modest …

Click here to view the original article.